Abstract:Yinyu Zhao, 1, 2 Nan Guo, 1, 3 Yidan Zhu, 1, 2 Jingyuan Shang, 4 Jiali Chen, 1, 3 Xingxian Luo, 1 Yi Liu, 1 Xiaohong Zhang, 1 Lin Huang 1 1 Department of Pharmacy, Peking University People's Hospital, Beijing, People's Republic of China; 2 School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China; 3 School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, People's Republic of China; 4 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pharmacy, Peking University Cancer Hospital and Institute, Beijing, People's Republic of China Correspondence: Xiaohong Zhang; Lin Huang, Department of Pharmacy, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, People's Republic of China, Email ; Several population pharmacokinetic (PPK) models of B cell lymphoma-2 (BCL-2) venetoclax (VEN) have been developed and published to characterize the influencing factors of pharmacokinetics in hematologic malignancies. This review described PPK models of VEN examining the magnitude and types of covariate effects in PK parameters, as well as identified areas that require further investigation in order to facilitate their use. Currently, there are six analyses on PPK models of VEN summarized in this review. Most analyses described the pharmacokinetics of VEN with a two-compartment model and all covariates are categorical. The median estimated apparent clearance (CL/F) was 446 L/Day and apparent volume of distribution of the central compartment (V 2 /F) was 114.5 L. The median IIV of CL/F reported was 39.5% and V 2 /F was 46.7%. Most commonly, CYP3A inhibitors, OATP1B3 inhibitors and rituximab co-administration were found to be significant covariates on CL/F. In addition, sex and population were influential covariates on V 2 /F. A detailed description of the characteristics of PPK models of VEN is provided in this review, as well as the effects of covariates on the PK parameters. For future development of the VEN PPK model, CYP3A inhibitors, rituximab co-administration, OATP1B1 transporter inhibitors, sex, population, and food might be considered. Further research and comprehensive investigations should be undertaken to explore reference ranges for therapeutic drug monitoring, define the potential role of patients with cerebrospinal fluid complications, and assess new or potential covariates. These endeavors will facilitate the development of personalized VEN therapy. Keywords: venetoclax, BCL-2 inhibitor, population pharmacokinetics, PPK model, systematic review Direct stimulation of the mitochondrial apoptotic pathway is a new therapeutic strategy in the current targeted therapy of hematologic malignancies. B cell lymphoma-2 (BCL-2) family is a key apoptotic factor in the endogenous apoptotic signaling pathway, which inhibits apoptosis and plays an important role in tumorigenesis and development. 1 Many hematological tumors show the overexpression of the anti-apoptotic protein BCL-2, 2–4 such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), so BCL-2 inhibitors have a broad application prospect in hematological malignancies. Venetoclax (VEN) is the world's first approved oral BCL-2 inhibitor targeting the apoptotic pathway in tumors. By binding directly to BCL-2, VEN displaces and releases pro-apoptotic proteins, ultimately leading to apoptosis of malignant cells. 5–7 This mechanism of action targets BCL-2 protein and is innovative and unique. The Food and Drug Administration (FDA) granted an accelerated approval to it. 8 Currently, FDA has approved the use of VEN in primary and relapsed or refractory (R/R) CLL/small lymphocytic leukemia (SLL), as well as newly diagnosed AML in patients who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. VEN has been approved for marketing in China by the end of 2020 and entered the national health insurance catalog in early 2023. However, due to the short period of time since its approval, there is little experience in clinical application. Despite its widespread use, consensus on its standardized clinical application and patient management has not been reached. The pharmacokinetic (PK) characteristics of VEN are established. 9–11 A peak plasma concentration (Cmax) is achieved in 5 to 8 hours following oral administration. 12 However, the safe range of blood concentrations and monitoring protocols are currently inconclusive. Based on av -Abstract Truncated-

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax

Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS

Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)

Risk analysis of enfortumab vedotin: A real-world approach based on the FAERS database

A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin

A real-world drug safety surveillance study of lenvatinib from the FAERS database

Novel Insights into Post-Marketing Adverse Events Associated with Lenvatinib: A Comprehensive Analysis Utilizing the FAERS Database

Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database

Population Pharmacokinetic Models of Venetoclax in Hematologic Malignancies: A Systematic Review

Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database

Efficacy and Safety of Venetoclax in Combination with Cytarabine and Azacitidine (VAA) in Relapsed/refractory Acute Myeloid Leukemia: an Open-Label, Single-Arm, Phase II Study.

Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database

Safety of talimogene laherparepvec: a real-world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)

Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib

A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag

Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System

A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database

Effects of age, sex, daily dose, comorbidity and co‐medication on venlafaxine‐associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA Adverse Event Reporting System database

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?